Resumen: Puma Biotechnology y Pierre Fabre firman acuerdo de licencia exclusiva para desarrollar y comercializar NERLYNX® (neratinib) en Europa | Business Wire
La EMA recomienda no aprobar el fármaco de Puma Biotech
Puma Biotech Inc. is looking forward to going to the top - Industry Global News24
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
ICOMPRE 2 DE CADA CAJA puma biotechnology jobs Y OBTENGA UN 70% DE DESCUENTO!
Puma Biotech Plunges on Sharp Drop in Cancer-Drug Sales - TheStreet
Puma Biotechnology Surging
SEC charges former Puma biotech exec with $1.1 million in insider trading
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology falls more than 20%
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict - Los Angeles Business Journal
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Puma Biotech Gets $100M Loan to Boost Breast Cancer Drug - Los Angeles Business Journal
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters.com
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ https://t.co/LR02TGd4oT" / Twitter
Puma Biotechnology
Why Puma Biotechnology Is Soaring Today | The Motley Fool
